Key Takeaways
- Lenalidomide cliff masks underlying strength: Consolidated revenue fell 1.5% YoY as the U.S. generic base ex-lenalidomide delivered strong double-digit growth, India grew 17%, and Emerging Markets jumped 24%.
- Gross margin snaps back, semaglutide relaunch locked in: Gross margin rebounded 562 bps QoQ to 52.1% after a prior-quarter provision, and management confirmed the semaglutide API scale-up problem is solved with a November 2026 relaunch backed by orders already in hand.
- Abatacept is the next needle-mover: A December 2026 U.S. launch is being prepared, with management estimating a fair IV market share of 15% to 25% and revenue potential in the hundreds of millions of dollars, though a CRL remains possible.
- The 25% EBITDA ambition is back on the table: Management called 20-21% margins "not impressive" and is targeting the "famous 25%," with semaglutide success pushing margins to 21%-plus in the near term.
- What to watch next quarter: The abatacept FDA decision by the December 22 goal date, the semaglutide relaunch execution in November, and whether raw material cost pressure persists into Q3 as expected.
Semaglutide: The Relaunch
- API scale-up solved: The problem that triggered the prior-quarter inventory provision has been fixed; API has been shipped to the partner, and drug product validation using that API takes about three weeks, with completion expected by November.
- Orders in hand: Management's confidence rests on orders already received, not on forecasts; most quantities are destined for Canada, with some volumes going to Latin America and a small amount to Africa.
- Regulatory progress continued during the pause: Approvals were pursued across 89 target markets while the scale-up issue was being resolved, though some were delayed because samples needed to be shipped.
- Device run rate: A tentative estimate of 1.2 crore to 1.5 crore pens over 12 months from April, contingent on the success of the current 0.6-0.7 crore device volumes and a clearer read on markets and competition.
- Launch cadence: Brazil likely at the beginning of Q4; most smaller markets at the end of Q3 or beginning of Q4; some in December, some in January, all within that window.
Israeli: "So I'm very confident. The confidence is based on orders that we already have. And we just obviously need to supply. The main issue was with our ability to scale up the API this problem is solved, and we shipped all the necessary API to our partner to do."
Abatacept: The Next Big Bet
- The opportunity: Management sees abatacept as a product that "should be in the hundreds of millions of dollars," anchoring the biosimilar revenue stream over the coming years, followed by pembrolizumab and daratumumab within five years.
- Approval timeline and risk: The plant has been inspected and the goal date is December 22; management feels good about the product, the inspection, and FDA correspondence, but explicitly acknowledges a CRL is possible.
- Launch mechanics: Initial sales possible from day one in smaller quantities, with full ramp-up after roughly six months once all codes and registrations are secured; the U.S. sales and marketing infrastructure is already built, with only a couple more hires pending.
- Market share ambition: Fair IV market share estimated at 15% to 25%, depending on launch success; the subcutaneous formulation filing is expected in the February-March 2027 quarter, adding to market share later.
- Manufacturing and geography: All markets will be supplied from the Bachupally facility; the European market is significant and launch there will follow the U.S. by a short interval.
Israeli: "I believe that a fair market share can be any number of 15% to 25% depends, of course, on the success of the launch."
Israeli: "You know, I'm 33 years in this business. And I had my share scars from these predictions. We feel good about the product. We feel good about the inspection. We feel good about the correspondence with the U.S. FDA. We want and be preparing to launch in December. If you ask me, is there a chance that we'll get a CRL, there is a chance."
Geographic Performance
| Market | Trend | Commentary |
|---|---|---|
| North America | ▼ 29% YoY | Lenalidomide decline drove the headline drop; the underlying base business ex-lenalidomide delivered strong double-digit growth on new launches including Sugammadex. |
| India | ▲ 17% YoY | Growth was driven by recent launches, including acquired brands, along with price increases and higher volumes; four brands featured in IPM top 50 new launches. |
| Emerging Markets | ▲ 24% YoY | Broad-based growth from new product launches across markets, acquisitions, favorable currency, and milestone income from Russia. |
| Europe | ▼ 6% YoY | Price erosion in generics and the ongoing impact of the NRT operating model change post-Haleon carve-out weighed on performance; ex-NRT, Germany was a drag. |
| PSAI | ▼ 19% YoY | API merchant business declined as older products lost demand and peptide customers shifted to finished goods; B2B finished product growth is recognized in other segments. |
- NRT business model transition: Flat revenue for two quarters reflects the shift from selling through Haleon to selling directly or via distributors, which removes Haleon margin payments and results in lower sales but higher profitability; two more quarters of year-over-year comparison distortion remain.
- India growth durability: Branded generics with investment behind them are performing well; the rest of the market is driven mostly by prices; management wants growth higher than market growth by a few basis points.
Margins: The Path Back to 25%
- Gross margin recovery: The 562 bps QoQ jump to 52.1% was driven by new high-margin products (bosutinib, sugammadex, nivolumab), a favorable business mix with India, EM and NRT now at 53% of revenue, and flat expenses while sales grew double-digit.
- Raw material headwind: Increases in KSMs, solvents and logistics freight from India exports due to the war are hitting EBITDA by close to 100 bps and are expected to persist through Q3 and Q4, with no additional growth unless geopolitics worsen further.
- SG&A at a plateau: SG&A at 32% of revenue is expected to stay at this level for coming quarters with small changes, as cost productivity becomes visible; the 6% YoY increase reflects annual increments, adverse forex, and elevated freight costs from Middle East supply chain disruptions.
- R&D normalizing lower: R&D fell 16% YoY and 9% QoQ on lower generic development expenditure; coming quarters are expected in the 7-8% of revenue range.
- The 25% target: Management called 20-21% margins "not impressive" and is aiming for the "famous 25%" EBITDA margin; if semaglutide launches successfully, margins will reach 21%-plus in the near term, with further expansion driven by EM, India, consumer health, and U.S. growth plus expense control.
Israeli: "For me, by the way, 20% or 21% is not impressive. We always said that we want 25%. We are recovering from lenalidomide, and that's what we are going to be."
Biosimilars & Complex Generics Pipeline
- Rituximab U.S. approval secured: FDA approval received; commercialization in the U.S. will be through partner Fresenius Kabi; in Europe, capacity constraints limit upside and high competition means no significant market share change is expected even after capacity addition.
- Nivolumab launched in India: Marks entry into biosimilar immuno-oncology in India; both rituximab and nivolumab are developed and manufactured in-house at Bachupally.
- Complex injectables on the horizon: Additional launches including complex injectables are planned during the year, described as "meaningful products," but management is cautious about promising timelines given past experience with complex generic approvals; launches depend on FDA approvals, not IP outcomes.
- Biosimilar manufacturing strategy: Leveraging Bachupally facilities plus additional future facilities, supplemented by licensing products from partners globally or for specific regions.
Israeli: "But I'm kind of careful to promise because I got burned in the past when dealing with the approval of complex generics. And some of you who have been with us for many, many years, and you remember that. But let's say, we have some exciting products ahead."
Partnerships, CDMO & Other Updates
- Dengue vaccine with Takeda: Partnered to bring Qdenga, India's first approved dengue vaccine, to private markets in India in the first half of 2027.
- Gilead collaboration expanded: Enabling access to investigational once-yearly lenacapavir for HIV prevention across 120 countries.
- Zoliflodacin approval in Thailand: Secured approval within six months of U.S. FDA approval, in collaboration with the GARDP Foundation.
- CDMO milestone: The CDMO business under Origin Pharmaceutical Services generated over $100 million in revenue in the last 12 months, with double-digit growth during the quarter; management expects 2x to 3x growth in the next three to four years, driven by discovery contracts, big-company production transfers, and Phase II/III projects.
- China JV: First generic approval for icotinib obtained in July; sales have started; Dr. Reddy's records its 51% share of profit, not the top line.
- Bendamustine licensing: Product rights licensed to a partner for better overall economics; included in this quarter's sales; the Russia milestone is part of EM revenue.
- Finance income swing: Finance income dropped from ~₹290 crores in Q1 to ~₹90 crores in Q2 because of a significant ruble spot rate movement from June to September, creating a P&L debit this quarter.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Semaglutide relaunch | Relaunch both directly and to partners, subject to successful validation | November 2026 |
| Gross margin range | 50% to 55%; Q2 at 52.1% is in that zone | Coming quarters |
| R&D spend | 7% to 8% of revenues | Coming quarters |
| SG&A level | ~32% of revenue with small changes | Coming quarters |
| EBITDA margin | 20%-plus sustainable; aiming for 25%; 21%-plus if semaglutide launches successfully | Ongoing / near term |
| NRT growth | High single-digit to double-digit | Ongoing |
| India growth | High double-digit, higher than market growth | Ongoing |
| Abatacept U.S. launch | Launch upon approval; full ramp-up ~6 months after | December 2026 goal date |
| Abatacept subcutaneous filing | Submission to FDA | February-March 2027 |
| Abatacept IV market share | 15% to 25% of IV market initially | At launch |
| CDMO revenue | 2x to 3x of current $100 mn-plus run rate | Next 3-4 years |
| Capex | ~₹1,600-1,700 crores (lower than earlier ₹1,800 crore guidance) | Full year FY27 |
| Semaglutide device run rate | 1.2-1.5 crore pens, tentative, contingent on current volume success | 12 months from April |
| Raw material cost pressure | Increases in KSMs, solvents, freight to continue; no additional growth barring further geopolitics | Q3 and Q4 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹8,671 cr ($905 mn), -1.5% YoY and +7.4% QoQ |
| Underlying base business growth (ex-lenalidomide) | Double-digit YoY, across North America, emerging markets and India |
| EBITDA margin | 20.6%, -614 bps YoY and +806 bps QoQ |
| Gross profit margin | 52.1%, -254 bps YoY and +562 bps QoQ |
| Global Generics gross margin | 56.2% |
| PSAI gross margin | 11.8% |
| Profit after tax | ₹925 cr ($97 mn), margin 10.7% on revenues |
| Diluted EPS | ₹11.1 |
| R&D spend | ₹524 cr, -16% YoY, 6% of revenues; expected to be 7-8% in coming quarters |
| SG&A spend | ₹2,808 cr, +6% YoY, 32% of revenue |
| Effective tax rate | 25.6% vs 22.2% in Q2 FY26 |
| North America generics revenue | $264 mn, -29% YoY and +12% QoQ, 29% of overall revenue |
| India business revenue | ₹1,851 cr, +17% YoY and +8% QoQ, 21% of overall revenue |
| India moving quarterly total growth | 21% vs IPM 14.7% |
| India IPM rank | 8 for the quarter, 9 for the year (IQVIA Sep 2026) |
| Emerging markets revenue | ₹2,059 cr, +24% YoY and +12% QoQ, 25% of overall revenue |
| European business revenue (incl. NRT) | €127 mn, -6% YoY and -3% QoQ, 16% of overall revenue |
| PSAI revenue | $88 mn, -19% YoY and -3% QoQ, 10% of overall revenue |
| CDMO trailing 12-month revenue | >$100 mn, expected to reach 2x-3x in 3-4 years |
| Net cash surplus | ₹2,502 cr ($261 mn) as of Sep 30, 2026 |
| Operating working capital | ₹14,650 cr ($1.53 bn), +₹297 cr over Jun 30, 2026 |
| Cash capex (quarter) | ₹186 cr ($19 mn); full-year guidance ₹1,600-1,700 cr |
| Semaglutide device guidance | 0.6-0.7 cr devices this year; tentative run rate of 1.2-1.5 cr pens for 12 months from April |
| Raw material and freight cost impact | ~100 bps drag on EBITDA |
| Rituximab market share in Europe | Low single digit |